Literature DB >> 21936751

Compensation effects on clinical trial data collection in opioid-dependent young adults.

Claire E Wilcox1, Michael P Bogenschutz, Masato Nakazawa, George E Woody.   

Abstract

BACKGROUND: Attrition in studies of substance use disorder treatment is problematic, potentially introducing bias into data analysis.
OBJECTIVES: This study aimed to determine the effect of participant compensation amounts on rates of missing data and observed rates of drug use.
METHODS: We performed a secondary analysis of a clinical trial of buprenorphine/naloxone among 152 treatment-seeking opioid-dependent subjects aged 15-21 during participation in a randomized trial. Subjects were randomized to a 2-week detoxification with buprenorphine/naloxone (DETOX; N = 78) or 12 weeks buprenorphine/naloxone (BUP; N = 74). Participants were compensated $5 for weekly urine drug screens and self-reported drug use information and $75 for more extensive assessments at weeks 4, 8, and 12.
RESULTS: Though BUP assignment decreased the likelihood of missing data, there were significantly less missing data at 4, 8, and 12 weeks than other weeks, and the effect of compensation on the probability of urine screens being positive was more pronounced in DETOX subjects.
CONCLUSION: These findings suggest that variations in the amount of compensation for completing assessments can differentially affect outcome measurements, depending on treatment group assignment. SCIENTIFIC SIGNIFICANCE: Adequate financial compensation may minimize bias when treatment condition is associated with differential dropout and may be a cost-effective way to reduce attrition. Moreover, active users may be more likely than non-active users to drop out if compensation is inadequate, especially in control groups or in groups who are not receiving active treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21936751      PMCID: PMC3745824          DOI: 10.3109/00952990.2011.600393

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  24 in total

1.  Contingency management reinforcement procedures for adolescent substance abuse.

Authors:  Y Kaminer
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-10       Impact factor: 8.829

Review 2.  Voucher-based incentives. A substance abuse treatment innovation.

Authors:  Stephen T Higgins; Sheila M Alessi; Robert L Dantona
Journal:  Addict Behav       Date:  2002 Nov-Dec       Impact factor: 3.913

3.  A replicable model for achieving over 90% follow-up rates in longitudinal studies of substance abusers.

Authors:  Christy K Scott
Journal:  Drug Alcohol Depend       Date:  2004-04-09       Impact factor: 4.492

4.  Methods for the analysis of binary outcome results in the presence of missing data.

Authors:  K L Delucchi
Journal:  J Consult Clin Psychol       Date:  1994-06

5.  Give them prizes, and they will come: contingency management for treatment of alcohol dependence.

Authors:  N M Petry; B Martin; J L Cooney; H R Kranzler
Journal:  J Consult Clin Psychol       Date:  2000-04

6.  Voucher-based reinforcement of opiate plus cocaine abstinence in treatment-resistant methadone patients: effects of reinforcer magnitude.

Authors:  J Dallery; K Silverman; M A Chutuape; G E Bigelow; M L Stitzer
Journal:  Exp Clin Psychopharmacol       Date:  2001-08       Impact factor: 3.157

7.  What does it take to retain substance-abusing adolescents in research protocols? Delineation of effort required, strategies undertaken, costs incurred, and 6-month post-treatment differences by retention difficulty.

Authors:  Kathleen Meyers; Alicia Webb; Jeanne Frantz; Mary Randall
Journal:  Drug Alcohol Depend       Date:  2003-01-24       Impact factor: 4.492

8.  One-year follow-up of psychotherapy and pharmacotherapy for cocaine dependence. Delayed emergence of psychotherapy effects.

Authors:  K M Carroll; B J Rounsaville; C Nich; L T Gordon; P W Wirtz; F Gawin
Journal:  Arch Gen Psychiatry       Date:  1994-12

9.  Investigating the missing data mechanism in quality of life outcomes: a comparison of approaches.

Authors:  Shona Fielding; Peter M Fayers; Craig R Ramsay
Journal:  Health Qual Life Outcomes       Date:  2009-06-22       Impact factor: 3.186

10.  Intention-to-treat meets missing data: implications of alternate strategies for analyzing clinical trials data.

Authors:  Charla Nich; Kathleen M Carroll
Journal:  Drug Alcohol Depend       Date:  2002-10-01       Impact factor: 4.492

View more
  6 in total

1.  Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.

Authors:  Paolo Mannelli; Li-Tzy Wu; Kathleen S Peindl; Marvin S Swartz; George E Woody
Journal:  Drug Alcohol Depend       Date:  2014-02-15       Impact factor: 4.492

2.  Active opioid use does not attenuate the humoral responses to inactivated influenza vaccine.

Authors:  Ekaterina Moroz; Randy A Albrecht; Brandon Aden; Ann Bordwine Beeder; Jianda Yuan; Adolfo García-Sastre; Brian R Edlin; Mirella Salvatore
Journal:  Vaccine       Date:  2016-02-06       Impact factor: 3.641

3.  Extended-Release Injectable Naltrexone (XR-NTX) With Intensive Psychosocial Therapy for Amphetamine-Dependent Persons Seeking Treatment: A Placebo-Controlled Trial.

Authors:  Valgerdur Runarsdottir; Ingunn Hansdottir; Thorarinn Tyrfingsson; Magnus Einarsson; Karen Dugosh; Charlotte Royer-Malvestuto; Helen Pettinati; Jag Khalsa; George E Woody
Journal:  J Addict Med       Date:  2017 May/Jun       Impact factor: 3.702

Review 4.  Updated systematic review identifies substantial number of retention strategies: using more strategies retains more study participants.

Authors:  Karen A Robinson; Victor D Dinglas; Vineeth Sukrithan; Ramakrishna Yalamanchilli; Pedro A Mendez-Tellez; Cheryl Dennison-Himmelfarb; Dale M Needham
Journal:  J Clin Epidemiol       Date:  2015-06-10       Impact factor: 6.437

Review 5.  Buprenorphine for managing opioid withdrawal.

Authors:  Linda Gowing; Robert Ali; Jason M White; Dalitso Mbewe
Journal:  Cochrane Database Syst Rev       Date:  2017-02-21

6.  Concordance between self-report and urine drug screen data in adolescent opioid dependent clinical trial participants.

Authors:  Claire E Wilcox; Michael P Bogenschutz; Masato Nakazawa; George Woody
Journal:  Addict Behav       Date:  2013-06-13       Impact factor: 3.913

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.